Drug Trial Radar · NCT01677689
Study to Investigate the Efficacy and Safety of Apomivir®
Last checked: Nov 19, 2026Latest source record: May 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
196
Planned (sponsor's estimate)
Start
May 31, 2026
Primary completion
May 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Far East Bio-Tec Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 3, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Apomivir® is extracted from a proprietary spirulina strain, FEM-101, a kind of blue cyanobacterium with patented freeze-thaw lysis and extraction method. According to the preclinical studies, Apomivir® have been proven to have excellent broad-spectrum anti-viral ability, especially for seasonal influenza viruses (Influenza virus A and B) that may cause illness, paralysis and even death, especially in children and elderly people. This phase II study is designed to evaluate the efficacy and safety of Apomivir® (120 mg b.i.d.) in subjects with seasonal influenza.
Conditions
- Influenza
Interventions
Apomivir®Drug
Study Group: Apomivir® 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.
PlaceboDrug
Control Group: Placebo 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety profile of Apomivir® treatment (120 mg b.i.d.).Time frame: from day1 to day 29, the entire treatment period and follow-up period.
- To evaluate the time to resolution of influenza symptoms defined as all flu symptom scores ≤ 1 after initiation of study treatment.Time frame: from day 1 to day 29, depends on the time to sympton resolution of individual subjects.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
China Medical University Hospital
Taichung, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.